

CITATION REPORT

List of articles citing

Preclinical profile of docetaxel (taxotere): efficacy as a single agent and in combination

DOI: PM/8604451

Seminars in Oncology, 1995, 22, 3-16.

Source: <https://exaly.com/paper-pdf/130038738/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
652	Novel Substances in the Treatment of Lung Cancer for the Radiation Oncologist. 2005 , 447-460		
651	Drug Evaluation: Oncologic, Endocrine & Metabolic: Docetaxel (Taxotere [®]): current status and clinical prospects. 1995 , 4, 1185-1195		2
650	High-dose chemotherapy with autologous bone marrow/stem-cell rescue in lung cancer. 1996 , 347, 847-8		6
649	The clinical pharmacology of etoposide: an update. 1996 , 22, 179-221		42
648	Chapter 34. To Market, To Market - 1995. 1996 , 31, 337-355		18
647	Nucleosides and nucleotides. 152. 1-(3-C-Ethynyl- β -ribo-pentofuranosyl)uracil as a broad spectrum antitumor nucleoside. <i>Bioorganic and Medicinal Chemistry Letters</i> , 1996 , 6, 1887-1892	2.9	36
646	Taxotere. 1996 , 13, 43-5		
645	Neo-adjuvant high-dose chemotherapy with autologous peripheral blood stem cell transplantation for inoperable relapse of nuchal liposarcoma resistant to standard-dose chemotherapy. 1996 , 7, 871		4
644	Frequent loss of heterozygosity on chromosomes 3p and 17p without VHL or p53 mutations suggests involvement of unidentified tumor suppressor genes in follicular thyroid carcinoma. 1997 , 82, 3684-91		74
643	Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 100 consecutive patients with limited- and extensive-disease small-cell lung cancer. 1997 , 8, 49-56		23
642	The enzyme ribonucleotide reductase: target for antitumor and anti-HIV therapy. 1997 , 34, 503-28		71
641	Overexpression and large-scale production of recombinant L-methionine-alpha-deamino-gamma-mercaptomethane-lyase for novel anticancer therapy. 1997 , 9, 233-45		104
640	Docetaxel in combination with doxorubicin or vinorelbine. 1997 , 33 Suppl 7, S20-2		16
639	Phase II trials of docetaxel (Taxotere) in advanced ovarian cancer--an updated overview. 1997 , 33, 2167-70		97
638	Characterisation of genotoxic properties of 2',2'-difluorodeoxycytidine. 1997 , 393, 165-73		15
637	Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 107 consecutive patients with limited- and extensive-stage non-small-cell lung cancer. 1997 , 8, 57-64		10
636	Renal cell carcinoma: Pathological prognostic criteria. 1997 , 64, 165-186		

635	Pharmacology of Cancer Chemotherapy in the Older Person. 1997 , 13, 169-183	103
634	New Agents in the Management of Non-Small Cell Lung Cancer. 1997 , 4, 317-325	4
633	Cytogenetic classification of renal cell cancer. 1997 , 95, 103-7	52
632	The von Hippel-Lindau tumor suppressor gene. A rare and intriguing disease opening new insight into basic mechanisms of carcinogenesis. 1997 , 93, 74-83	52
631	Phase II trial of paclitaxel and ifosfamide as a salvage treatment in metastatic breast cancer. 1997 , 45, 47-53	11
630	Issues in experimental design and endpoint analysis in the study of experimental cytotoxic agents in vivo in breast cancer and other models. 1997 , 46, 255-78	46
629	[High dose chemotherapy of solid tumors]. 1997 , 92, 410-4	2
628	Anthracycline-Resistant Breast Cancer. 1997 , 4, 221-227	2
627	The Clinical Utility of Docetaxel in Adriamycin-Resistant Breast Cancer. 1997 , 4, 273-279	2
626	Improved method to prepare RNA-free DNA from mammalian cells. 1997 , 702, 61-8	9
625	Treatment for non-Hodgkin's lymphoma (stage I, II) of the elderly: usefulness of local and regional irradiation and reduced dose chemotherapy. 1997 , 37, 87-92	9
624	Fatal pulmonary toxicity resulting from treatment with gemcitabine. 1997 , 80, 286-91	149
623	Cancer chemotherapy in the older patient. 1997 , 80, 1317-1322	98
622	Mobilization, collection, and characterization of peripheral blood hemopoietic progenitors after chemotherapy with epirubicin, paclitaxel, and granulocyte-colony stimulating factor administered to patients with metastatic breast carcinoma. 1998 , 82, 867-873	7
621	A randomized trial of hybrid administration of cyclophosphamide, doxorubicin, and vincristine (CAV)/Cisplatin and etoposide (PVP) versus sequential administration of CAV-PVP for the treatment of patients with small cell lung carcinoma. 1998 , 83, 283-290	10
620	[Current developments in use of docetaxel (taxotere) in gynecologic oncology]. 1998 , 93 Suppl 3, 4-15	
619	Nucleosides and nucleotides. 176. 2'-Deoxy-2'-hydroxylaminocytidine: a new antitumor nucleoside that inhibits DNA synthesis although it has a ribonucleoside structure. <i>Bioorganic and Medicinal Chemistry Letters</i> , 1998 , 8, 1913-8	2.9 5
618	Experiences of 23 patients > or = 90 years of age treated with radiation therapy. 1998 , 41, 407-13	47

617	Radiosensitizing potential of gemcitabine (2',2'-difluoro-2'-deoxycytidine) within the cell cycle in vitro. 1998 , 41, 875-82	81
616	A review of the pharmacology and clinical activity of new chemotherapeutic agents in lung cancer. 1998 , 24, 35-53	17
615	Postconfluent multilayered cell line cultures for selective screening of gemcitabine. 1998 , 34, 921-6	29
614	Lymphoma at the extremes of age. 1998 , 14, 302-11	4
613	Utilization of molecular genetics in the differentiation between adrenal cortical adenomas and carcinomas. 1998 , 29, 518-21	17
612	Phase II trial assessing the combination of gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC). 1998 , 22, 139-48	37
611	An alternative route for multistep tumorigenesis in a novel case of hereditary renal cell cancer and a t(2;3)(q35;q21) chromosome translocation. 1998 , 62, 1475-83	64
610	New agents in the treatment of small cell lung cancer. 1998 , 113, 86S-91S	12
609	Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors. 1998 , 9, 1003-8	75
608	Genitourinary Cancers in Older Adults. 1998 , 14, 333-366	4
607	Anemia of Aging: A Model of Erythropoiesis in Cancer Patients. 1998 , 5, 17-21	25
606	Ribonucleotide reductases in the twenty-first century. 1998 , 95, 2723-4	87
605	Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma. 1999 , 10, 33-8	119
604	Severe pulmonary toxicity in patients treated with a combination of docetaxel and gemcitabine for metastatic transitional cell carcinoma. 1999 , 10, 943-7	70
603	Renal cell cancer: chromosome 3 translocations as risk factors. 1999 , 91, 1159-60	49
602	The role of single-agent gemcitabine in the treatment of non-small-cell lung cancer. 1999 , 10 Suppl 5, S53-6	10
601	Gemcitabine transport in xenopus oocytes expressing recombinant plasma membrane mammalian nucleoside transporters. 1999 , 91, 1876-81	201
600	Additive and supra-additive cytotoxicity of cisplatin-taxane combinations in ovarian carcinoma cell lines. 1999 , 79, 286-92	35

599	Is age a barrier to the aggressive treatment of ovarian cancer with paclitaxel and carboplatin?. 1999 , 75, 464-7	19
598	[The intensification of the radiotherapeutic effect on HeLa cells by gemcitabine]. 1999 , 175, 78-83	16
597	Gemcitabine cytotoxicity of human malignant glioma cells: modulation by antioxidants, BCL-2 and dexamethasone. 1999 , 365, 301-8	44
596	Additive action of gemcitabine (2',2'-difluorodeoxycytidine) and 2-chlorodeoxyadenosine on murine leukemias L1210 and P388. 1999 , 17, 95-101	14
595	Should chemotherapy be used as a treatment of advanced colorectal carcinoma (ACC) in patients over 70 years of age?. 1999 , 35, 1643-1647	4
594	Quelles nouvelles drogues peut-on utiliser dans les associations chimioradiothérapie ?. 1999 , 3, 28s-41s	1
593	Human thymidine kinase 2: molecular cloning and characterisation of the enzyme activity with antiviral and cytostatic nucleoside substrates. 1999 , 443, 170-4	116
592	Gemcitabine and other new chemotherapeutic agents for the treatment of metastatic bladder cancer. 1999 , 53, 243-50	14
591	Chemotherapy for advanced hormone refractory prostate cancer. 1999 , 54, 30-5	84
590	Autologous stem-cell transplantation for solid tumors in adults. 1999 , 13, 939-68, vi	8
589	Concurrent chemoradiation in the treatment of head and neck cancer. 1999 , 13, 719-42, vi-vii	21
588	Hematopoietic stem cell transplantation for small cell lung cancer. 1999 , 116, 531S-538S	8
587	Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas. 2000 , 11, 325-9	59
586	A phase II trial of palliative docetaxel plus 5-fluorouracil for squamous-cell cancer of the head and neck. 2000 , 11, 535-9	17
585	Growth inhibitory effects of paclitaxel on human epithelioid sarcoma in vitro: heterogeneity of response and the multidrug resistance phenotype. 2000 , 88, 1614-22	6
584	A phase II trial of biweekly high dose gemcitabine for patients with metastatic pancreatic adenocarcinoma. 2000 , 88, 2505-11	41
583	Developments in chemotherapy of breast cancer. 2000 , 88, 3073-3079	70
582	Comparison of 2-methoxyestradiol-induced, docetaxel-induced, and paclitaxel-induced apoptosis in hepatoma cells and its correlation with reactive oxygen species. 2000 , 89, 983-994	104

581	Pharmacokinetics of gemcitabine and 2',2'-difluorodeoxyuridine in a patient with ascites. 2000 , 20, 1204-7	6
580	Basis for effective combination cancer chemotherapy with antimetabolites. 2000 , 87, 227-53	216
579	Hemopoietic reserve in the older cancer patient: clinical and economic considerations. 2000 , 7, 539-47	64
578	NCIC-CTG phase II study of gemcitabine in patients with malignant glioma (IND.94). 2000 , 11, 315-8	23
577	Psychologic Issues, Practitioners' Interventions, and the Relationship of Both to an Interdisciplinary Breast Center Team. 2000 , 9, 347-365	3
576	Precancerous Lesions in the Kidney. 2000 , 34, 136-165	4
575	A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancer. 2000 , 18, 521-9	157
574	Anaemia in cancer: pathophysiology and treatment. 2000 , 26, 303-11	145
573	Two weekly vinorelbine: administration in patients who have received at least two prior chemotherapy regimes for advanced breast cancer. 2000 , 36, 177-82	34
572	Biomarkers of renal cell carcinoma. Past and future considerations. 2000 , 5, 139-148	5
571	Antineoplastic chemotherapy of the older cancer patient. 2000 , 14, 193-212, x-xi	80
570	2000 Highlights from: 36th Annual ASCO Meeting; New Orleans, LA May 2000. 2000 , 1, 180-185	
569	Clinical pharmacokinetics of 2'-deoxy-2'-methylidenecytidine (DMDC), a deoxycytidine analogue antineoplastic agent. 2000 , 38, 475-91	5
568	The Influence of advanced age on the treatment and prognosis of diffuse large-cell lymphoma (DLCL). 2001 , 1, 278-84	17
567	Gemcitabine and pemetrexed disodium combinations in vitro and in vivo. 2001 , 34 Suppl 4, S103-5	9
566	Nuclear factor-kappa B is upregulated in colorectal cancer. 2001 , 130, 363-9	237
565	Gemcitabine and vinorelbine as first-line chemotherapy for advanced non-small cell lung cancer: a phase II trial. 2001 , 37, 583-90	29
564	Combination chemotherapy of the taxanes and antimetabolites: its use and limitations. 2001 , 37, 2310-23	48

563	Treatment of advanced ovarian cancer. 2001 , 37 Suppl 9, S1-7		23
562	Cemp, a mitoxantrone containing combination, in the treatment of intermediate and high grade non-hodgkin's lymphoma: an effective and non toxic therapeutic alternative for adult and elderly patients. 2001 , 41, 125-36		2
561	The Geriatric Cancer Patient: Equal benefit from Equal treatment. 2001 , 8, 1-25		60
560	Patogēse molekular do feocromocitoma. 2001 , 45, 507-519		1
559	Phase I dose-finding and pharmacokinetic study of docetaxel and vinorelbine as first-line chemotherapy for metastatic breast cancer. 2001 , 12, 909-18		15
558	Combination chemotherapy with docetaxel plus vinorelbine in metastatic breast cancer patients with prior exposure to anthracyclines. 2001 , 12, 1061-5		12
557	Chemotherapy in elderly patients with colorectal cancer. 2001 , 12, 435-42		62
556	Phase II trial of the use of paclitaxel and gemcitabine as a salvage treatment in metastatic breast cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2001 , 24, 264-8	2.7	36
555	Docetaxel alone or orally combined with 5-fluorouracil and its derivatives: effects on mouse mammary tumor cell line MM2 in vitro and in vivo. 2001 , 12, 691-8		9
554	Phase I trial of gemcitabine and CPT-11 given weekly for four weeks every six weeks. 2001 , 12, 627-31		6
553	Hematopoietic responses to stress conditions in young dogs compared with elderly dogs. 2001 , 98, 322-7		20
552	Evolution of breast cancer management: focus on neoadjuvant chemotherapy. 2001 , 8, 339-50		2
551	Locally advanced breast cancer: is surgery necessary?. 2001 , 7, 131-7		21
550	Enhancement of tumor radioresponse by combined chemotherapy in murine hepatocarcinoma. 2001 , 16, 883-9		24
549	Taxanes in lung cancer: a review with focus on the European experience. 2001 , 38, 105-27		14
548	Developments in cytotoxic chemotherapy: advances in treatment utilising vinorelbine. 2001 , 40, 251-63		24
547	Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies. 2001 , 92, 1567-76		24
546	Effects of docetaxel in combination with radiation on human head and neck cancer cells (ZMK-1) and cervical squamous cell carcinoma cells (CaSki). 2001 , 91, 840-5		35

545	Hypermethylation of the CpG island of the RASSF1A gene in ovarian and renal cell carcinomas. 2001 , 94, 212-7		137
544	Molecular analysis of a familial case of renal cell cancer and a t(3;6)(q12;q15). 2001 , 31, 23-32		30
543	Breast cancer survival and in vitro tumor response in the extreme drug resistance assay. 2001 , 66, 225-37		40
542	Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both an anthracycline and a taxane. 2001 , 66, 83-7		68
541	Nucleoside analogues: mechanisms of drug resistance and reversal strategies. 2001 , 15, 875-90		381
540	Inhibitor of apoptosis-1 (IAP-1) expression and apoptosis in non-small-cell lung cancer cells exposed to gemcitabine. 2001 , 62, 13-9		40
539	Activation of caspases and induction of apoptosis by novel ribonucleotide reductase inhibitors amidox and didox. 2001 , 29, 623-32		34
538	Docetaxel: overview of an active drug for breast cancer. <i>Oncologist</i> , 2001 , 6 Suppl 3, 1-4	5.7	25
537	A phase II Hoosier Oncology Group study of vinorelbine and estramustine phosphate in hormone-refractory prostate cancer. 2002 , 13, 435-40		20
536	The cancer patient and quality of life. <i>Oncologist</i> , 2002 , 7, 120-5	5.7	203
535	Gemcitabine-induced pulmonary toxicity: case report and review of the literature. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2002 , 25, 96-100	2.7	66
534	Role of deoxycytidine kinase (dCK) activity in gemcitabine's radioenhancement in mice and human cell lines in vitro. 2002 , 63, 329-38		26
533	Phase I/II trial of gemcitabine plus cyclophosphamide in patients with metastatic breast carcinoma previously treated with taxanes. 2002 , 2, 299-303		7
532	Pemetrexed (Alimta) and gemcitabine in breast cancer patients previously treated with anthracyclines and taxanes. 2002 , 3 Suppl 1, 21-3		3
531	Chemoradiation with novel agents for rectal cancer. 2002 , 2, 24-30		12
530	Treatment paradigms in aggressive non-Hodgkin's lymphoma in elderly patients. 2002 , 3 Suppl 1, S12-8		6
529	The role of myelopoietic growth factors in managing cancer in the elderly. 2002 , 62 Suppl 1, 47-63		14
528	Nucleoside analogues and nucleobases in cancer treatment. 2002 , 3, 415-24		434

527	Combination effects of alkylphosphocholines and gemcitabine in malignant and normal hematopoietic cells. 2002 , 182, 163-74	34
526	Variation in the kinetics of caspase-3 activation, Bcl-2 phosphorylation and apoptotic morphology in unselected human ovarian cancer cell lines as a response to docetaxel. 2002 , 63, 733-43	49
525	The activity profile of the hexacyclic camptothecin derivative DX-8951f in experimental human colon cancer and ovarian cancer. 2002 , 64, 1267-77	26
524	Expression of a non-functional p53 affects the sensitivity of cancer cells to gemcitabine. 2002 , 97, 439-45	84
523	A prospective, randomized trial comparing neoadjuvant chemotherapy with radiotherapy alone in patients with advanced nasopharyngeal carcinoma. 2002 , 94, 2217-23	145
522	Phase II trial of gemcitabine in advanced sarcomas. 2002 , 94, 3225-9	90
521	Nonneutropenic febrile episodes associated with docetaxel-based chemotherapy in patients with solid tumors. 2002 , 95, 1326-33	10
520	Chemotherapy of lung cancer in the elderly. 2002 , 41, 349-61	19
519	Management of small-cell lung cancer in the elderly. 2002 , 41, 79-88	22
518	Phase I study of weekly gemcitabine as a radiation sensitizer for unresectable pancreatic cancer. 2002 , 54, 670-6	35
517	Gynecological malignancies in elderly patients: is age 70 a limit to standard-dose chemotherapy? An Italian retrospective toxicity multicentric study. 2002 , 85, 445-50	39
516	Docetaxel plus vinorelbine as salvage chemotherapy in advanced breast cancer: a phase II study. 2002 , 76, 47-56	17
515	Complications of cytotoxic chemotherapy in older patients: focus on myelotoxicity in lymphomas. 2003 , 48, S27-31	4
514	Pharmacology of cytotoxic agents: a helpful tool for building dose adjustment guidelines in the elderly. 2003 , 48, 199-214	11
513	Aging and the hemopoietic system. 2003 , 48, S3-S12	22
512	Metastatic renal cell carcinoma. 2003 , 4, 385-90	200
511	Previously unidentified changes in renal cell carcinoma gene expression identified by parametric analysis of microarray data. 2003 , 3, 31	200
510	Enhanced effectiveness of last generation antiproliferative compounds vs. cisplatin on malignant pleural mesothelioma cell lines. 2003 , 473, 83-95	7

509	Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxel. 2003 , 91, 417-29	191
508	Overview of bladder cancer trials in the Cancer and Leukemia Group B. 2003 , 97, 2090-8	31
507	Measuring the side effects of taxane therapy in oncology: the functional assesment of cancer therapy-taxane (FACT-taxane). 2003 , 98, 822-31	205
506	A phase I study of radiation therapy and twice-weekly gemcitabine and cisplatin in patients with locally advanced pancreatic cancer. 2003 , 55, 1305-10	27
505	A rapid and sensitive liquid chromatography/tandem mass spectrometry method for determination of docetaxel in human plasma. 2003 , 17, 1548-52	45
504	DJ-927, a novel oral taxane, overcomes P-glycoprotein-mediated multidrug resistance in vitro and in vivo. 2003 , 94, 459-66	71
503	Docetaxel induction therapy in locally advanced squamous cell carcinoma of the head and neck. 2003 , 88, 11-7	35
502	A new multidrug reinduction protocol with topotecan, vinorelbine, thiotepa, dexamethasone, and gemcitabine for relapsed or refractory acute leukemia. 2003 , 17, 1967-72	35
501	Newer approaches to gemcitabine-based therapy of pancreatic cancer: fixed-dose-rate infusion and novel agents. 2003 , 56, 24-30	18
500	The basic biology and immunobiology of renal cell carcinoma: considerations for the clinician. 2003 , 30, 423-36	17
499	New agents in the treatment of small-cell lung cancer: focus on gemcitabine. 2003 , 4 Suppl 2, S56-63	5
498	Gemcitabine-Based Therapy in Relapsed Non-Hodgkin's Lymphoma and Cutaneous T-Cell Lymphoma. 2003 , 4, 152-153	1
497	Novel approaches to treating the asymptomatic hormone-refractory prostate cancer patient. 2003 , 62 Suppl 1, 147-54	12
496	Phase I study of the combination of gemcitabine and nedaplatin for treatment of previously untreated advanced non-small cell lung cancer. 2003 , 39, 91-7	13
495	Concurrent two-dimensional radiotherapy and weekly docetaxel in the treatment of stage III non-small cell lung cancer: a good local response but no good survival due to radiation pneumonitis. 2003 , 40, 79-84	70
494	New chemotherapy agents in veterinary medicine. 2003 , 33, 629-49, viii	15
493	Use and abuse of taxanes in the management of metastatic breast cancer. 2003 , 39, 1978-89	21
492	Genotoxicity of two anticancer drugs, gemcitabine and topotecan, in mouse bone marrow in vivo. 2003 , 537, 43-51	63

491	Synergistic effect of sequential administration of mitoguazone (MGBG) and gemcitabine in treating tissue cultured human breast cancer cells and mammary rat tumors. 2003 , 21, 217-26		2
490	A phase I study of gemcitabine and docetaxel for advanced stage solid tumors. 2003 , 21, 350-4		6
489	Docetaxel: an alternative taxane in ovarian cancer. 2003 , 89 Suppl 3, S9-S15		63
488	Phase I clinical study of infusional 5-fluorouracil with oxaliplatin and gemcitabine (FOG regimen) in patients with solid tumors. 2003 , 14, 1682-7		4
487	Pemetrexed (Alimta): a novel multitargeted antifolate agent. 2003 , 3, 145-56		74
486	Biweekly docetaxel and vinorelbine in anthracycline-resistant metastatic breast cancer: a multicenter phase II study. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2003 , 26, 127-31	2.7	14
485	Phase II trial of the use of gemcitabine and 5-fluorouracil in the treatment of advanced pancreatic and biliary tract cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2003 , 26, 151-4	2.7	26
484	Docetaxel as adjuvant and neoadjuvant treatment for patients with breast cancer. 2004 , 5, 2147-57		3
483	Effects of paclitaxel and docetaxel on EGFR-expressing human carcinoma cells under normoxic versus hypoxic conditions in vitro. 2004 , 16, 372-80		17
482	Docetaxel, cisplatin and 5-fluorouracil in patients with locally advanced unresectable head and neck cancer: a phase I-II feasibility study. 2004 , 15, 638-45		61
481	Weekly combination of docetaxel and vinorelbine in metastatic breast cancer: a phase I/II study. 2004 , 67, 257-61		6
480	Cytochrome P450 CYP1B1 activity in renal cell carcinoma. 2004 , 91, 966-71		40
479	Phase II trial of gemcitabine concurrent with radiation for locally advanced squamous cell carcinoma of the head and neck. 2004 , 15, 301-6		26
478	Granisetron: an update on its clinical use in the management of nausea and vomiting. <i>Oncologist</i> , 2004 , 9, 673-86	5.7	62
477	Identification and analysis of single-nucleotide polymorphisms in the gemcitabine pharmacologic pathway. 2004 , 4, 307-14		76
476	Enhancement of Ad-p53 therapy with docetaxel in head and neck cancer. 2004 , 114, 1871-9		22
475	Depletion of deoxyribonucleoside triphosphate pools in tumor cells by nitric oxide. 2004 , 36, 507-16		22
474	Nuclear factor Y regulation and promoter transactivation of human ribonucleotide reductase subunit M2 gene in a Gemcitabine resistant KB clone. 2004 , 67, 1499-511		21

473	Molecular pathology of renal cell carcinoma. 2004 , 43 Suppl 3, S118-9		
472	A phase I trial of gemcitabine plus cladribine in patients with advanced hematologic malignant diseases. 2004 , 54, 553-61		4
471	Phase I clinical trial of fixed-dose rate infusional gemcitabine and dacarbazine in the treatment of advanced soft tissue sarcoma, with assessment of gemcitabine triphosphate accumulation. 2004 , 101, 2261-9		16
470	Intracellular cargo delivery using tat peptide and derivatives. 2004 , 24, 1-12		112
469	Prophylaxis versus treatment: is there a better way to manage radiotherapy-induced nausea and vomiting?. 2004 , 60, 1018-25		21
468	Investigation of the pharmacokinetics of gemcitabine and 2',2'-difluorodeoxyuridine in human plasma by liquid chromatography. 2004 , 332, 234-7		14
467	Radiation and third-generation chemotherapy. 2004 , 18, 55-80		31
466	Phase I study of docetaxel and irinotecan in patients with advanced non-small-cell lung cancer. 2004 , 45, 85-91		15
465	Front-line weekly chemotherapy with gemcitabine for unfit patients with non-small cell lung cancer (NSCLC). 2004 , 45, 373-80		9
464	Biweekly docetaxel and vinorelbine as first-line chemotherapy in metastatic breast cancer. 2004 , 5, 131-5		15
463	Role of 2'-2' difluorodeoxycytidine (gemcitabine)-induced cell cycle dysregulation in radio-enhancement of human head and neck squamous cell carcinomas. 2004 , 70, 55-61		8
462	Docetaxel versus paclitaxel for adjuvant treatment of ovarian cancer: case-control analysis of toxicity. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2004 , 27, 14-8	2.7	26
461	Docetaxel plus 5-fluorouracil in locally recurrent and/or metastatic squamous cell carcinoma of the head and neck: a phase II multicenter study. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2004 , 27, 472-6	2.7	19
460	Graft-versus-tumor effect against advanced pancreatic cancer after allogeneic reduced-intensity stem cell transplantation. 2005 , 79, 821-7		24
459	Gemcitabine inhibits viability, growth, and metastasis of osteosarcoma cell lines. 2005 , 23, 964-9		25
458	Synthesis and biological evaluation of gemcitabine-lipid conjugate (NEO6002). <i>Bioorganic and Medicinal Chemistry Letters</i> , 2005 , 15, 2571-4	2.9	44
457	Gemcitabine monotherapy in recurrent ovarian cancer: from the bench to the clinic. 2005 , 15 Suppl 1, 12-7		24
456	FT-IR microspectroscopy as a tool to assess lung cancer cells response to chemotherapy. 2005 , 38, 179-184		41

455	Immunosenescence and macrophage functional plasticity: dysregulation of macrophage function by age-associated microenvironmental changes. 2005 , 205, 60-71		158
454	Preclinical experience with docetaxel in gastrointestinal cancers. <i>Seminars in Oncology</i> , 2005 , 32, S3-9	5,5	11
453	Combination chemotherapy with gemcitabine and vinorelbine in the treatment of relapsed or refractory diffuse large B-cell lymphoma: a phase-II trial by the Hellenic Cooperative Oncology Group. 2005 , 75, 124-9		22
452	A phase II study of paclitaxel, carboplatin, and gemcitabine in previously untreated patients with epithelial ovarian cancer FIGO stage IC-IV (AGO-OVAR protocol OVAR-8). 2005 , 96, 444-51		23
451	The role of clofarabine in hematologic and solid malignancies--development of a next-generation nucleoside analog. 2005 , 103, 1985-95		74
450	Incorporation of OSI-7836 into DNA of Calu-6 and H460 xenograft tumors. 2005 , 55, 213-21		8
449	A novel phospholipid gemcitabine conjugate is able to bypass three drug-resistance mechanisms. 2005 , 56, 15-21		58
448	A phase IB study of the pharmacokinetics of gemcitabine and pemetrexed, when administered in rapid sequence to patients with advanced solid tumors. 2005 , 55, 522-30		22
447	Granisetron in the control of radiotherapy-induced nausea and vomiting: a comparison with other antiemetic therapies. 2005 , 13, 671-8		11
446	Gemcitabine as prolonged infusion and vinorelbine in anthracycline and/or taxane pretreated metastatic breast cancer: a phase II study. 2005 , 131, 568-74		10
445	Gynecologic oncology group trials of chemotherapy for metastatic and recurrent cervical cancer. 2005 , 7, 419-34		62
444	Gemcitabine and mitoxantrone in metastatic breast cancer: a phase-I-study. 2005 , 23, 349-56		3
443	Prolonged infusion of gemcitabine in advanced solid tumors: a phase-I-study. 2005 , 23, 139-46		8
442	Sequence dependent potentiation of gemcitabine by flavopiridol in human breast cancer cells. 2005 , 90, 25-31		16
441	Identification of fatty acid binding proteins as markers associated with the initiation and/or progression of renal cell carcinoma. 2005 , 5, 2631-40		35
440	Primary chemotherapy with gemcitabine as prolonged infusion, non-pegylated liposomal doxorubicin and docetaxel in patients with early breast cancer: final results of a phase II trial. 2005 , 16, 1624-31		29
439	A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors. 2005 , 16, 958-65		42
438	Grundlagen der Chemotherapie. 2005 , 612-617		

437	Antimetabolites. 2006 , 1-18	
436	Combination of gemcitabine and Ad5/3-Delta24, a tropism modified conditionally replicating adenovirus, for the treatment of ovarian cancer. 2005 , 12, 1198-205	70
435	Molecularly targeted therapy in renal cell carcinoma. 2005 , 5, 1031-40	29
434	Toxicity of intraperitoneal chemotherapy may be related to age in women treated for optimally debulked ovarian cancer. 2005 , 2, 271-275	5
433	Inhibition of different intracellular signal cascades in human pancreatic cancer cells. 2005 , 5, 251-8	3
432	Combined chemoradiotherapy in small cell lung cancer. 2005 , 19, 321-42, vii	4
431	Role of anemia in survival of patients with elderly aggressive non-Hodgkin's lymphoma after chemotherapy. 2005 , 46, 1449-54	6
430	Phase I and pharmacokinetic study of docetaxel combined with melphalan and carboplatin, with autologous hematopoietic progenitor cell support, in patients with advanced refractory malignancies. 2005 , 11, 297-306	5
429	Combination chemotherapy with docetaxel, estramustine and suramin for hormone refractory prostate cancer. 2005 , 23, 93-101	13
428	Germ cell tumors: an update of recent data and review of active protocols in stage I and metastatic disease. 2005 , 23, 293-302	2
427	Comparative pharmacokinetics and metabolic pathway of gemcitabine during intravenous and intra-arterial delivery in unresectable pancreatic cancer patients. 2005 , 44, 957-67	17
426	Concepts and clinical trials of dose-dense chemotherapy for breast cancer. 2005 , 6, 402-11	7
425	SU11248 and AG013736: current data and future trials in renal cell carcinoma. 2005 , 4, 175-80	16
424	Ribonucleotide reductase M1 gene promoter activity, polymorphisms, population frequencies, and clinical relevance. 2005 , 47, 183-92	70
423	Phase I study of combination chemotherapy with gemcitabine and irinotecan for non-small cell lung cancer. 2005 , 48, 115-9	11
422	cN-II expression predicts survival in patients receiving gemcitabine for advanced non-small cell lung cancer. 2005 , 49, 363-70	54
421	Analysis of deoxycytidine accumulation in gemcitabine treated patients. 2006 , 25, 1225-32	3
420	Sorafenib. 2006 , 7, 453-61	79

419	Management of acute lymphoblastic leukemia in older patients. 2006 , 43, 126-33	48
418	Single Agent Gemcitabine Chemotherapy in Dogs with Spontaneously Occurring Lymphoma. 2006 , 20, 1384-1388	17
417	Head-to-head: docetaxel challenges paclitaxel. 2006 , 4, 4-8	13
416	Epidemiology of Kidney Cancer. 2006 , 5, 558-565	9
415	Cellular pharmacology of gemcitabine. 2006 , 17 Suppl 5, v7-12	447
414	Targeting growth factor and antiangiogenic pathways in clear-cell renal cell carcinoma: rationale and ongoing trials. 2006 , 5 Suppl 1, S31-9	4
413	Dose-finding study of fixed dose gemcitabine and escalating doses of ifosfamide given on days 1 and 8 in patients with advanced non-small cell lung cancer. 2006 , 53, 165-70	1
412	Monitoring of cell growth and assessment of cytotoxicity using electrochemical impedance spectroscopy. 2006 , 1760, 432-9	39
411	Cyclin dependent kinases as targets for cancer therapy. 2006 , 1, 311-332	6
410	Phase II study of gemcitabine in children with relapsed acute lymphoblastic leukemia or acute myelogenous leukemia (ADV0022): a Children's Oncology Group Report. 2006 , 46, 193-7	17
409	Pharmacokinetics of gemcitabine and its primary metabolite in dogs after intravenous bolus dosing and its in vitro pharmacodynamics. 2006 , 29, 137-45	13
408	Pharmacokinetics of gemcitabine and its primary metabolite in dogs after intravenous infusion. 2006 , 29, 147-52	10
407	A new, simple method for quantifying gemcitabine triphosphate in cancer cells using isocratic high-performance liquid chromatography. 2006 , 97, 1274-8	11
406	Phase I/II trial of doxorubicin and fixed dose-rate infusion gemcitabine in advanced soft tissue sarcomas: a GEIS study. 2006 , 94, 1797-802	2
405	A pharmacokinetic interaction study of docetaxel and cisplatin plus or minus 5-fluorouracil in the treatment of patients with recurrent or metastatic solid tumors. 2006 , 58, 673-80	13
404	Phase II trial of a 2-h infusion of gemcitabine plus carboplatin as first-line chemotherapy for advanced non-small-cell lung cancer. 2007 , 59, 1-7	12
403	VEGF-targeted therapy in renal cell carcinoma: active drugs and active choices. 2006 , 8, 85-9	10
402	Phase II study of neoadjuvant docetaxel/ vinorelbine followed by surgery and adjuvant doxorubicin/cyclophosphamide in women with stage II/III breast cancer. 2006 , 6, 511-7	12

401	A dose escalation study of gemcitabine plus pemetrexed administered biweekly in patients with solid tumors. 2006 , 71, 197-203		9
400	A phase II trial of a combination of pemetrexed and gemcitabine in patients with metastatic breast cancer: an NCCTG study. 2006 , 17, 226-31		15
399	Review of the pemetrexed and gemcitabine combination in patients with advanced-stage non-small cell lung cancer. 2006 , 17 Suppl 5, v86-90		14
398	Combinations of Taxanes and Ionizing Radiation. 2006 , 35-51		
397	Clinical studies of pemetrexed and gemcitabine combinations. 2006 , 17 Suppl 5, v29-32		14
396	10-year update on chemotherapy for non-small cell lung cancer. 2006 , 17 Suppl 5, v33-36		20
395	Pharmacokinetic evaluation of gemcitabine and 2',2'-difluorodeoxycytidine-5'-triphosphate after prolonged infusion in patients affected by different solid tumors. 2006 , 17 Suppl 5, v142-7		22
394	An association between RRM1 haplotype and gemcitabine-induced neutropenia in breast cancer patients. <i>Oncologist</i> , 2007 , 12, 622-30	5-7	46
393	Potential of mammary cancer inhibition by combination of antagonists of growth hormone-releasing hormone with docetaxel. 2007 , 104, 1943-6		35
392	Sublethal concentrations of gemcitabine (2',2'-difluorodeoxycytidine) alter mitochondrial ultrastructure and function without reducing mitochondrial DNA content in BxPC-3 human pancreatic carcinoma cells. 2007 , 26, 911-21		6
391	The rationale for and the current role of chemoradiotherapy. 2007 , 6, 11-19		6
390	Phase I study of irinotecan and gemcitabine in previously untreated patients with advanced non-small cell lung cancer. 2007 , 37, 353-7		5
389	Phase II feasibility study of concurrent radiotherapy and gemcitabine in chemo-naïve patients with squamous cell carcinoma of the head and neck: long-term follow up data. 2007 , 18, 1856-60		15
388	Particularités de l'usage des agents cytotoxiques chez le sujet âgé. 2007 , 89-97		
387	Current treatment paradigms for locally advanced non-small cell lung cancer. 2007 , 2 Suppl 2, S77-85		33
386	Targeted therapies for kidney cancer in urologic practice. 2007 , 25, 420-32		13
385	Modern Therapeutic Approaches in Metastatic Renal Cell Carcinoma. 2007 , 5, 26-37		10
384	Pharmacokinetics in cancer chemotherapy. 2007 , 43, 271-82		21

383	Phase I and pharmacokinetic study of gemcitabine administered at fixed-dose rate, combined with docetaxel/melphalan/carboplatin, with autologous hematopoietic progenitor-cell support, in patients with advanced refractory tumors. 2007 , 13, 1324-37		11
382	Gemcitabine-induced reversible posterior leukoencephalopathy syndrome: a case report and review of the literature. <i>Oncologist</i> , 2007 , 12, 1332-5	5-7	53
381	MRI-measured water mobility increases in response to chemotherapy via multiple cell-death mechanisms. 2007 , 20, 602-14		58
380	Response of choline metabolites to docetaxel therapy is quantified in vivo by localized (31)P MRS of human breast cancer xenografts and in vitro by high-resolution (31)P NMR spectroscopy of cell extracts. 2007 , 58, 270-80		47
379	Gemcitabine in advanced biliary tract cancers. 2007 , 61, 230-42		16
378	Aging and the dendritic cell system: implications for cancer. 2007 , 64, 90-105		59
377	Encapsulation of gemcitabine lipophilic derivatives into polycyanoacrylate nanospheres and nanocapsules. 2007 , 344, 71-7		88
376	Candidate biomarkers in renal cell carcinoma. 2007 , 7, 4601-12		32
375	Active and passive immunotherapy: vaccines and antibodies. 2007 , 99, 1301-4		4
374	Cellular localization and functional characterization of the equilibrative nucleoside transporters of antitumor nucleosides. 2007 , 98, 1633-7		32
373	Gemcitabine-oxaliplatin combination in heavily pretreated metastatic breast cancer: a pilot study on 43 patients. 2007 , 13, 165-71		11
372	An increase of cytochrome C oxidase mediated disruption of gemcitabine incorporation into DNA in a resistant KB clone. 2007 , 73, 1927-38		4
371	Structure, expression and function of HLA-G in renal cell carcinoma. 2007 , 17, 444-50		27
370	Cytotoxic therapy for advanced pancreatic adenocarcinoma. <i>Seminars in Oncology</i> , 2007 , 34, 347-53	5-5	61
369	Phase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomas. 2007 , 59, 251-9		22
368	Gemcitabine and vinorelbine in recurrent advanced non-small cell lung cancer: sequence does matter. 2007 , 59, 621-9		8
367	Vinorelbine/docetaxel combination treatment of metastatic breast cancer: a phase I study. 2007 , 60, 365-73		6
366	Pharmacokinetics of gemcitabine in tumor and non-tumor extracellular fluid of brain: an in vivo assessment in rats employing intracerebral microdialysis. 2008 , 61, 223-9		33

365	The role of nucleoside transporters in cancer chemotherapy with nucleoside drugs. 2007 , 26, 85-110	183
364	Tyrosine kinase inhibitors and anti-angiogenic therapies in kidney cancer. 2007 , 8, 211-26	8
363	Fluorinated Nucleosides: Synthesis and Biological Implication. 2008 , 129, 743-766	143
362	Fixed dose-rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma: a dose-finding study. 2008 , 87, 79-84	12
361	Does saturable formation of gemcitabine triphosphate occur in patients?. 2008 , 63, 55-64	18
360	Gemcitabine at fixed dose-rate in patients with advanced soft-tissue sarcomas: a mono-institutional phase II study. 2008 , 63, 149-55	25
359	[Von-Hippel-Lindau gene mutation types. Association of gene expression signatures in clear cell renal cell carcinoma]. 2008 , 29 Suppl 2, 303-7	2
358	Antibody therapy in renal cell carcinoma. 2008 , 26, 141-6	5
357	Clinical study of docetaxel-vinorelbine as second-line chemotherapy in advanced non-small cell lung cancer. 2008 , 7, 200-202	
356	Loss of PL6 protein expression in renal clear cell carcinomas and other VHL-deficient tumours. 2008 , 214, 46-57	5
355	Unsaturated fluoro-ketopyranosyl nucleosides: synthesis and biological evaluation of 3-fluoro-4-keto-beta-d-glucopyranosyl derivatives of N(4)-benzoyl cytosine and N(6)-benzoyl adenine. 2008 , 43, 420-8	25
354	Nucleoside analogs: molecular mechanisms signaling cell death. 2008 , 27, 6522-37	163
353	Carbonic anhydrase IX/G250/MN: a molecule too good to be true?. 2008 , 101, 527-8	10
352	Carbonic anhydrase IX: historical and future perspectives. 2008 , 101 Suppl 4, 2-7	174
351	Population pharmacokinetics of gemcitabine and its metabolite in patients with cancer: effect of oxaliplatin and infusion rate. 2008 , 65, 326-33	16
350	Antitumoral activity of PEG-gemcitabine prodrugs targeted by folic acid. 2008 , 127, 239-48	138
349	Phase II trial of low-dose gemcitabine in prolonged infusion and cisplatin for advanced non-small cell lung cancer. 2008 , 60, 208-14	10
348	A Phase II study of capecitabine and vinorelbine in patients with metastatic breast cancer pretreated with anthracyclines and taxanes. 2008 , 8, 149-54	30

347	Molecular genetics of hereditary renal cancer: new genes and diagnostic and therapeutic opportunities. 2008 , 8, 895-905	7
346	Targeted nanoassembly loaded with docetaxel improves intracellular drug delivery and efficacy in murine breast cancer model. 2008 , 5, 1044-54	44
345	Fluorine-19 or Phosphorus-31 NMR Spectroscopy. 2008 , 369-406	
344	Primary chemotherapy with low-dose prolonged infusion gemcitabine and cisplatin in patients with bladder cancer: a Phase II trial. 2008 , 26, 133-6	16
343	Phase I evaluation of gemcitabine, mitoxantrone, and their effect on plasma disposition of fludarabine in patients with relapsed or refractory acute myeloid leukemia. 2008 , 49, 1523-9	2
342	Comparative investigations of cytotoxic action of anticancer drugs Taxol and Taxotere on meristematic cells of <i>Allium cepa</i> . 2008 , 61, 26-44	3
341	Kinetic investigation of the inhibitory effect of gemcitabine on DNA polymerization catalyzed by human mitochondrial DNA polymerase. 2008 , 283, 15339-48	23
340	Extensive metabolism and hepatic accumulation of gemcitabine after multiple oral and intravenous administration in mice. 2008 , 36, 1606-15	25
339	Overcoming S-phase checkpoint-mediated resistance: sequence-dependent synergy of gemcitabine and 7-ethyl-10-hydroxycamptothecin (SN-38) in human carcinoma cell lines. 2008 , 74, 724-35	8
338	The interaction between taxoids and serine/threonine protein phosphatase activities during taxan-induced apoptosis of HL 60 leukemic cells. 2008 , 13, 215-23	2
337	Characteristics and pharmacokinetics of docetaxel liposome containing Tween 80 or PEG-DSPE. 2008 , 18, 253-257	5
336	Docetaxel in the treatment of advanced non-small-cell lung cancer. 2008 , 8, 1207-22	41
335	Paclitaxel and docetaxel in the treatment of breast cancer. 2008 , 9, 2603-16	83
334	S-phase cell-specific modification by gemcitabine of PFGE-analyzed radiation-induced DNA fragmentation and rejoining. 2008 , 84, 770-7	3
333	Prolonged versus standard gemcitabine infusion: translation of molecular pharmacology to new treatment strategy. <i>Oncologist</i> , 2008 , 13, 261-76	5-7 59
332	Gemcitabine pharmacogenomics: deoxycytidine kinase and cytidylate kinase gene resequencing and functional genomics. 2008 , 36, 1951-9	24
331	Dramatic response of acute monoblastic leukemia to a single dose of docetaxel. 2008 , 49, 577-80	1
330	Outpatient chemotherapy plus radiotherapy in sarcomas: improving cancer control with radiosensitizing agents. 2008 , 15, 38-46	52

329	Phospholipid/deoxycytidine analogue prodrugs for the treatment of cancer. 2009 , 19, 31-36	7
328	Gemcitabine and vinorelbine therapy for patients with Hodgkin lymphoma. 2009 , 3, 525-532	
327	Docetaxel microemulsion for enhanced oral bioavailability: preparation and in vitro and in vivo evaluation. 2009 , 140, 86-94	231
326	Glycogen synthase kinase-3 inhibition disrupts nuclear factor-kappaB activity in pancreatic cancer, but fails to sensitize to gemcitabine chemotherapy. 2009 , 9, 132	44
325	Antitumor activity of a novel antisense oligonucleotide against Akt1. 2009 , 108, 832-8	24
324	Poor outcome of elderly patients with platinum-sensitive recurrent ovarian cancer: results from the SOCRATES retrospective study. 2009 , 71, 233-41	27
323	Antitumor effects of KITC, a new resveratrol derivative, in AsPC-1 and BxPC-3 human pancreatic carcinoma cells. 2009 , 27, 393-401	22
322	Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma. 2009 , 64, 907-16	54
321	Experimental study of combination therapy with S-1 against pancreatic cancer. 2009 , 64, 1211-9	14
320	Retention studies of 2'-2'-difluorodeoxycytidine and 2'-2'-difluorodeoxyuridine nucleosides and nucleotides on porous graphitic carbon: development of a liquid chromatography-tandem mass spectrometry method. 2009 , 1216, 3168-74	42
319	VEGF: Biologic Aspects and Clinical Approaches. 2009 , 99-118	
318	Phase II study of weekly gemcitabine and vinorelbine for children with recurrent or refractory Hodgkin's disease: a children's oncology group report. 2009 , 27, 1456-61	45
317	Aging in the lympho-hematopoietic stem cell compartment. 2009 , 30, 360-5	81
316	Paclitaxel alters the expression and specific activity of deoxycytidine kinase and cytidine deaminase in non-small cell lung cancer cell lines. 2009 , 28, 76	6
315	Os genes ERCC1 e RRM1 no carcinoma broncopulmonar. 2009 , 15, 683-696	1
314	Gemcitabine-based chemogene therapy for pancreatic cancer using Ad-dCK::UMK GDEPT and TS/RR siRNA strategies. 2009 , 11, 637-50	57
313	[ERCC1 and RRM1 genes in lung cancer]. 2009 , 15, 683-96	2
312	A phase II study of concurrent chemoradiation with weekly docetaxel, carboplatin, and radiation therapy followed by consolidation chemotherapy with docetaxel and carboplatin for locally advanced inoperable non-small cell lung cancer (NSCLC). 2009 , 4, 722-7	16

311	Gemcitabine and paclitaxel suppress the production of vascular endothelial growth factor induced by deferoxamine in human non-small cell lung cancer A549 cells. 2010 , 1, 853-857	10
310	Facile small scale synthesis of nucleoside 5'-phosphate mixtures. 2010 , 29, 14-26	6
309	A phase II study of oxaliplatin, docetaxel, and GM-CSF in patients with previously treated advanced melanoma. 2010 , 65, 509-14	13
308	Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism. <i>European Journal of Clinical Pharmacology</i> , 2010 , 66, 611-7	2.8 28
307	Long circulation and cytotoxicity of PEGylated gemcitabine and its potential for the treatment of pancreatic cancer. 2010 , 31, 9340-56	108
306	Fragile histidine triad protein: structure, function, and its association with tumorigenesis. 2010 , 136, 333-50	24
305	Impact of biomarkers on non-small cell lung cancer treatment. 2010 , 5, 5-17	14
304	Human blood and marrow side population stem cell and Stro-1 positive bone marrow stromal cell numbers decline with age, with an increase in quality of surviving stem cells: correlation with cytokines. 2010 , 131, 718-22	36
303	Algorithms for the treatment of patients with metastatic breast cancer and prior exposure to taxanes and anthracyclines. 2010 , 10 Suppl 2, S7-19	6
302	Individual and combined roles of CYP3A, P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) in the pharmacokinetics of docetaxel. 2010 , 127, 2959-64	44
301	Synthesis and in vitro cytotoxic activity on human anaplastic thyroid cancer cells of lipoamino acid conjugates of gemcitabine. 2010 , 71, 294-302	6
300	Dose-finding study and pharmacogenomic analysis of fixed-rate infusion of gemcitabine, irinotecan and bevacizumab in pretreated metastatic colorectal cancer patients. 2010 , 103, 1529-35	11
299	Pharmacokinetic study to optimize the intravesical administration of gemcitabine. 2010 , 106, 1652-6	11
298	Effects of systemic chemotherapy on the liver. 2010 , 9, 133-143	52
297	Prospects for the Use of ATR Inhibitors to Treat Cancer. 2010 , 3, 1311-1334	44
296	A human epidermal growth factor receptor 2 expression-based approach to neoadjuvant chemotherapy for operable breast cancer. 2010 , 40, 620-6	4
295	Interaction between DNA Polymerase lambda and anticancer nucleoside analogs. 2010 , 285, 16874-9	13
294	Challenges of drug resistance in the management of pancreatic cancer. 2010 , 10, 1647-61	38

293	In vivo delivery of silica nanorattle encapsulated docetaxel for liver cancer therapy with low toxicity and high efficacy. 2010 , 4, 6874-82	278
292	Tumors of the Urinary Tract. 2010 , 463-491	
291	The immunohistochemical overexpression of ribonucleotide reductase regulatory subunit M1 (RRM1) protein is a predictor of shorter survival to gemcitabine-based chemotherapy in advanced non-small cell lung cancer (NSCLC). 2010 , 70, 205-10	47
290	Intratumoral delivery of docetaxel enhances antitumor activity of Ad-p53 in murine head and neck cancer xenograft model. 2010 , 31, 78-83	2
289	Docetaxel inhibits progression of human hepatoma cell line in vitro and is effective in advanced hepatocellular carcinoma. 2010 , 40, 304-10	6
288	A critical analysis of the interplay between cytochrome P450 3A and P-glycoprotein: recent insights from knockout and transgenic mice. 2011 , 63, 390-410	85
287	ERK phosphorylation predicts synergism between gemcitabine and the epidermal growth factor receptor inhibitor AG1478. 2011 , 73, 274-82	8
286	Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma. 2011 , 25, 813-33	40
285	Overview of renal cell carcinoma pathways and drug targets. 2011 , 6-14	
284	High-throughput plasma docetaxel quantification by liquid chromatography-tandem mass spectrometry. 2011 , 412, 358-64	26
283	A phase I/II trial of non-pegylated liposomal doxorubicin, docetaxel and trastuzumab as first-line treatment in HER-2-positive locally advanced or metastatic breast cancer. 2011 , 47, 2091-8	25
282	The relationship between treatment time of gemcitabine and development of hematologic toxicity in cancer patients. 2011 , 34, 1765-8	12
281	Profilin 1 overexpression in renal cell carcinoma. 2011 , 18, 63-71	22
280	Gem-(R)CHOP versus (R)CHOP: a randomized phase II study of gemcitabine combined with (R)CHOP in untreated aggressive non-Hodgkin's lymphoma--EORTC lymphoma group protocol 20021 (EudraCT number 2004-004635-54). 2011 , 86, 111-6	7
279	Enhanced antiproliferative activity of Herceptin (HER2)-conjugated gemcitabine-loaded chitosan nanoparticle in pancreatic cancer therapy. 2011 , 7, 859-70	127
278	Development of docetaxel-loaded intravenous formulation, Nanoxel-PM using polymer-based delivery system. 2011 , 155, 262-71	115
277	Vitamin E TPGS coated liposomes enhanced cellular uptake and cytotoxicity of docetaxel in brain cancer cells. 2011 , 421, 332-40	138
276	Multi-core vesicle nanoparticles based on vesicle fusion for delivery of chemotherapeutic drugs. 2011 , 32, 7924-31	31

275	Cytostatic and cytotoxic drugs. 2011 , 33, 935-962	1
274	Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer. 2011 , 127, 153-62	15
273	Potential of amino acid/dipeptide monoester prodrugs of floxuridine in facilitating enhanced delivery of active drug to interior sites of tumors: a two-tier monolayer in vitro study. 2011 , 28, 2575-88	14
272	Gene expression analysis for predicting gemcitabine resistance in human cholangiocarcinoma. 2011 , 18, 700-11	29
271	Phase I-II trial of prolonged gemcitabine infusion plus paclitaxel as a biweekly schedule for advanced breast cancer patients pretreated with anthracyclines. 2011 , 67, 687-93	8
270	14-3-3 protein beta/alpha as a urinary biomarker for renal cell carcinoma: proteomic analysis of cyst fluid. 2011 , 401, 245-52	25
269	Biweekly vinorelbine and tegafur/uracil in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: GEICAM 2000-02 phase II study. 2011 , 13, 281-6	3
268	The new 5- or 6-azapyrimidine and cyanuric acid derivatives of l-ascorbic acid bearing the free C-5 hydroxy or C-4 amino group at the ethylenic spacer: CD-spectral absolute configuration determination and biological activity evaluations. 2011 , 46, 2770-85	11
267	Randomized phase II trial of irinotecan with paclitaxel or gemcitabine for non-small cell lung cancer: association of UGT1A1*6 and UGT1A1*27 with severe neutropenia. 2011 , 6, 121-7	23
266	Principes d'ăncogfiatrie. 2011 , 111-128	
265	The Ets transcription factor ELF5 functions as a tumor suppressor in the kidney. 2011 , 14, 316-22	12
264	DNA polymerase eta and chemotherapeutic agents. 2011 , 14, 2521-9	13
263	Impaired iron status in aging research. <i>International Journal of Molecular Sciences</i> , 2012 , 13, 2368-86	6.3 55
262	Pathway-based pharmacogenomics of gemcitabine pharmacokinetics in patients with solid tumors. 2012 , 13, 1009-21	22
261	Phase I trial of gemcitabine combined with capecitabine and erlotinib in advanced pancreatic cancer: a clinical and pharmacological study. 2012 , 58, 371-80	2
260	Surface-modified gemcitabine with mucoadhesive polymer for oral delivery. 2012 , 29, 487-96	7
259	Development of docetaxel-loaded vitamin E TPGS micelles: formulation optimization, effects on brain cancer cells and biodistribution in rats. 2012 , 7, 353-64	79
258	The nucleoside antagonist cordycepin causes DNA double strand breaks in breast cancer cells. 2012 , 30, 1917-25	43

257	In vitro mechanistic study of cell death and in vivo performance evaluation of RGD grafted PEGylated docetaxel liposomes in breast cancer. 2012 , 8, 951-62		34
256	Effect of genetic polymorphisms on therapeutic response and clinical outcomes in pancreatic cancer patients treated with gemcitabine. 2012 , 13, 1023-35		15
255	Gemcitabine-based induction chemotherapy and concurrent with radiation in advanced head and neck cancer. 2012 , 29, 3367-73		10
254	Docetaxel-loaded composite nanoparticles formed by a temperature-induced phase transition for cancer therapy. 2012 , 27, 441-452		6
253	High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies. 2012 , 18, 1677-86		35
252	Neoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer. 2012 , 7, 28		66
251	Combination therapy with gossypol reveals synergism against gemcitabine resistance in cancer cells with high BCL-2 expression. <i>PLoS ONE</i> , 2012 , 7, e50786	3-7	22
250	Antitumor effects of combining docetaxel (taxotere) with the antivascular action of ultrasound stimulated microbubbles. <i>PLoS ONE</i> , 2012 , 7, e52307	3-7	67
249	A multicenter, randomized, phase 2 clinical trial to evaluate the efficacy and safety of combination docetaxel and carboplatin and sequential therapy with docetaxel then carboplatin in patients with recurrent platinum-sensitive ovarian cancer. 2012 , 118, 3283-93		9
248	A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer. 2012 , 30, 1175-83		33
247	Age-stratified phase I trial of a combination of bortezomib, gemcitabine, and liposomal doxorubicin in patients with advanced malignancies. 2012 , 69, 1117-26		9
246	[Myelopoiesis and bone marrow function in elderly tumor patients]. 2012 , 45, 197-200		2
245	Response to gemcitabine-platinum chemotherapy by single nucleotide polymorphisms of RRM1 and ERCC1 genes in patients with non-small-cell lung cancer. 2012 , 3, 19-26		1
244	Concomitant chemoradiotherapy using low-dose weekly gemcitabine versus low-dose weekly paclitaxel in locally advanced head and neck squamous cell carcinoma: a phase III study. 2012 , 29, 279-84		8
243	Nutritional status independently affects quality of life of patients with systemic immunoglobulin light-chain (AL) amyloidosis. 2012 , 91, 399-406		27
242	High sensitive assay employing column switching chromatography to enable simultaneous quantification of an amide prodrug of gemcitabine (LY2334737), gemcitabine, and its metabolite dFdU in human plasma by LC-MS/MS. 2013 , 932, 117-22		10
241	Hyaluronic acid-coated liposomes for active targeting of gemcitabine. 2013 , 85, 373-80		107
240	A UFLC-MS/MS method coupled with one-step protein precipitation for determination of docetaxel in rat plasma: comparative pharmacokinetic study of modified nanostructured lipid carrier. 2013 , 83, 202-8		14

239	Off-label prescribing patterns of antiemetics in children: a multicenter study in Italy. 2013 , 172, 361-7	17
238	The development and clinical validation of a turbulent-flow liquid chromatography-tandem mass spectrometric method for the rapid quantitation of docetaxel in serum. 2013 , 417, 12-8	9
237	Can taxanes provide benefit in patients with CNS tumors and in pediatric patients with tumors? An update on the preclinical development of cabazitaxel. 2013 , 72, 515-28	28
236	Targeting ribonucleotide reductase for cancer therapy. 2013 , 17, 1423-37	56
235	Optimization of parameters for preparation of docetaxel-loaded PLGA nanoparticles by nanoprecipitation method. 2013 , 33, 754-758	13
234	New insights into the synergism of nucleoside analogs with radiotherapy. 2013 , 8, 223	13
233	Personalized medicine for targeted and platinum-based chemotherapy of lung and bladder cancer. 2013 , 5, 369-91	49
232	Agonists and antagonists induce different palonosetron dissociation rates in 5-HT _{2A} and 5-HT _{2B} receptors. 2013 , 73, 241-6	21
231	Docetaxel-loaded thermosensitive and bioadhesive nanomicelles as a rectal drug delivery system for enhanced chemotherapeutic effect. 2013 , 30, 1860-70	35
230	Physicochemical characterization and in vivo evaluation of solid self-nanoemulsifying drug delivery system for oral administration of docetaxel. 2013 , 30, 307-14	16
229	Comparative proteomic and phosphoproteomic profiling of pancreatic adenocarcinoma cells treated with CB1 or CB2 agonists. 2013 , 34, 1359-68	11
228	Chemotherapy in Patients with Anthracycline- and Taxane-Pretreated Metastatic Breast Cancer: An Overview. 2013 , 5, 42-50	44
227	In vitro and in vivo studies of pharmacokinetics and antitumor efficacy of D07001-F4, an oral gemcitabine formulation. 2013 , 71, 379-88	12
226	An integrative network inference approach to predict mechanisms of cancer chemoresistance. 2013 , 5, 458-73	3
225	Synthesis, characterization and antitumor evaluation of CMCS-DTX conjugates as novel delivery platform for docetaxel. 2013 , 451, 41-9	42
224	Inhibiting the growth of pancreatic adenocarcinoma in vitro and in vivo through targeted treatment with designer gold nanotherapeutics. <i>PLoS ONE</i> , 2013 , 8, e57522	3-7 23
223	Preclinical absorption, distribution, metabolism, and excretion of an oral amide prodrug of gemcitabine designed to deliver prolonged systemic exposure. 2013 , 5, 261-76	24
222	Enhanced breast cancer therapy with nsPEFs and low concentrations of gemcitabine. 2014 , 14, 98	15

221	Gemcitabine diphosphate choline is a major metabolite linked to the Kennedy pathway in pancreatic cancer models in vivo. 2014 , 111, 318-25		16
220	Upgrading gemcitabine with recycled kinase inhibitors. 2014 , 13, 2810-1		1
219	Characterization of permeability, stability and anti-HIV-1 activity of decitabine and gemcitabine divaleryl prodrugs. 2014 , 23, 223-30		11
218	Docetaxel-loaded chitosan microspheres as a lung targeted drug delivery system: in vitro and in vivo evaluation. <i>International Journal of Molecular Sciences</i> , 2014 , 15, 3519-32	6.3	46
217	A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors. 2014 , 25, 1416-1421		55
216	Enhanced antitumor efficacy of gemcitabine-loaded temperature-sensitive liposome by hyperthermia in tumor-bearing mice. 2014 , 40, 470-6		12
215	Regulation of hematopoietic stem cell aging by the small RhoGTPase Cdc42. 2014 , 329, 214-9		7
214	Differences in RRM1 protein expression between diagnostic biopsies and resection specimens, and changes during carboplatin and paclitaxel treatment, in non-small-cell lung cancer. 2014 , 64, 412-20		3
213	Prodrugs of phosphonates and phosphates: crossing the membrane barrier. 2015 , 360, 115-60		100
212	The dipeptide monoester prodrugs of floxuridine and gemcitabine-feasibility of orally administrable nucleoside analogs. 2014 , 7, 169-91		10
211	Targeting ATR in DNA damage response and cancer therapeutics. 2014 , 40, 109-17		124
210	Enhanced anticancer activity of a combination of docetaxel and Aneustat (OMN54) in a patient-derived, advanced prostate cancer tissue xenograft model. <i>Molecular Oncology</i> , 2014 , 8, 311-22	7.9	21
209	Low-dose versus standard-dose gemcitabine infusion and cisplatin for patients with advanced bladder cancer: a randomized phase II trial-an update. 2014 , 31, 811		9
208	A phase II study of docetaxel and vinorelbine plus filgrastim for HER-2 negative, stage IV breast cancer: SWOG S0102. 2014 , 143, 351-8		3
207	The role of Bax and Bcl-2 in gemcitabine-mediated cytotoxicity in uveal melanoma cells. 2014 , 35, 1169-75		12
206	Redox-responsive targeted gelatin nanoparticles for delivery of combination wt-p53 expressing plasmid DNA and gemcitabine in the treatment of pancreatic cancer. 2014 , 14, 75		50
205	Gemcitabine and docetaxel, an effective second-line chemotherapy for lung metastasis of urothelial carcinoma. 2014 , 19, 516-22		14
204	DNA-PKcs is important for Akt activation and gemcitabine resistance in PANC-1 pancreatic cancer cells. 2014 , 452, 106-11		25

203	Peritoneal cancer treatment. 2014 , 15, 623-36		35
202	Synthesis and biological evaluation of isoprenylated coumarins as potential anti-pancreatic cancer agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014 , 24, 4654-4658	2.9	27
201	Advances in the formulations of non-injection administration of docetaxel. 2014 , 22, 87-94		10
200	Effect of gemcitabine and retinoic acid loaded PAMAM dendrimer-coated magnetic nanoparticles on pancreatic cancer and stellate cell lines. 2014 , 68, 737-43		39
199	Gemcitabine-induced cardiomyopathy: a case report and review of the literature. 2014 , 8, 220		17
198	A phase II trial of prolonged, continuous infusion of low-dose gemcitabine plus cisplatin in patients with advanced malignant pleural mesothelioma. 2014 , 73, 975-82		21
197	Phase 1 dose escalation and pharmacokinetic evaluation of oral gemcitabine prodrug (LY2334737) in combination with docetaxel in patients with advanced solid tumors. 2014 , 73, 1205-15		6
196	Tumor-specific delivery and therapy by double-targeted DTX-CMCS-PEG-NGR conjugates. 2014 , 31, 475-88		21
195	One-electron oxidation of gemcitabine and analogs: mechanism of formation of C3' and C2' sugar radicals. 2014 , 136, 15646-53		12
194	Synthesis, characterization and mechanistic-insight into the anti-proliferative potential of PLGA-gemcitabine conjugate. 2014 , 470, 51-62		36
193	Micellar nanoparticles loaded with gemcitabine and doxorubicin showed synergistic effect. 2014 , 113, 158-68		27
192	Adjuvant Chemotherapy with Docetaxel, Cisplatin, and Continuous-Infusion 5-Fluorouracil for Gastric Cancer: A Phase II Study. 2014 , 7, 277-83		5
191	Docetaxel load biodegradable porous microspheres for the treatment of colorectal peritoneal carcinomatosis. 2014 , 69, 100-7		14
190	Phase I trial of MES, a novel polyethylene glycosylated recombinant human endostatin, plus gemcitabine in advanced pancreatic cancer. 2014 , 2, 586-590		3
189	A phase I combination dose-escalation study of eribulin mesylate and gemcitabine in patients with advanced solid tumours: a study of the Princess Margaret Consortium. 2015 , 113, 1534-40		8
188	Identification of the Lipodepsipeptide MDN-0066, a Novel Inhibitor of VHL/HIF Pathway Produced by a New Pseudomonas Species. <i>PLoS ONE</i> , 2015 , 10, e0125221	3.7	26
187	Modulating DNA methylation in activated CD8+ T cells inhibits regulatory T cell-induced binding of Foxp3 to the CD8+ T Cell IL-2 promoter. 2015 , 194, 990-8		5
186	Dual-action combination therapy enhances angiogenesis while reducing tumor growth and spread. 2015 , 27, 123-37		135

185	Regulation of mammalian nucleotide metabolism and biosynthesis. 2015 , 43, 2466-85	391
184	p-Hydroxy benzoic acid-conjugated dendrimer nanotherapeutics as potential carriers for targeted drug delivery to brain: an in vitro and in vivo evaluation. 2015 , 17, 1	15
183	BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts. 2015 , 113, 425-32	55
182	WEE1 kinase polymorphism as a predictive biomarker for efficacy of platinum-gemcitabine doublet chemotherapy in advanced non-small cell lung cancer patients. 2015 , 5, 11114	12
181	Regioselective chemical and rapid enzymatic synthesis of a novel redox α -Antiproliferative molecular hybrid. 2015 , 96, 47-57	7
180	Salvage therapy with gemcitabine, vinorelbine, and pegylated liposomal doxorubicin for relapsed or refractory pediatric Hodgkin lymphoma. Results of a retrospective series of four children. 2015 , 94, 1401-6	5
179	[Hematopoietic stem cell exhaustion and advanced glycation end-products in the unexplained anemia of the elderly]. 2015 , 50, 223-31	3
178	An open-label phase 1 dose-escalation clinical trial of a single intravenous administration of gemcitabine in dogs with advanced solid tumors. 2015 , 29, 620-5	2
177	Preanalytical Stability of Gemcitabine and its Metabolite 2', 2'-Difluoro-2'-Deoxyuridine in Whole Blood-Assessed by Liquid Chromatography Tandem Mass Spectrometry. 2015 , 104, 4427-4432	8
176	Efficient "green" encapsulation of a highly hydrophilic anticancer drug in metal-organic framework nanoparticles. 2015 , 23, 759-67	55
175	Phase I and pharmacological trial of lapatinib in combination with gemcitabine in patients with advanced breast cancer. 2015 , 33, 1197-205	8
174	Nucleoside Analog Activity in Malignant Melanoma Cell Lines. 2015 , 34, 639-49	
173	The Role of Hypoxia and Cancer Stem Cells in Renal Cell Carcinoma Pathogenesis. 2015 , 11, 919-43	59
172	Dose-dense paclitaxel in advanced ovarian cancer. 2015 , 27, 40-7	22
171	A phase I study of combination therapy with nanoparticle albumin-bound paclitaxel and cyclophosphamide in patients with metastatic or recurrent breast cancer. 2015 , 20, 474-9	3
170	An imaging-based platform for high-content, quantitative evaluation of therapeutic response in 3D tumour models. 2014 , 4, 3751	94
169	Co-administration with cell penetrating peptide enhances the oral bioavailability of docetaxel-loaded nanoparticles. 2015 , 41, 764-71	14
168	Delivery of Gemcitabine Prodrugs Employing Mesoporous Silica Nanoparticles. 2016 , 21, 522	24

167	Knockdown of POLA2 increases gemcitabine resistance in lung cancer cells. 2016 , 17, 1029	6
166	Nanotherapeutics promises for colorectal cancer and pancreatic ductal adenocarcinoma. 2016 , 147-201	1
165	Enhanced Antitumor Activity of Monophosphate Ester Prodrugs of Gemcitabine: In Vitro and In Vivo Evaluation. 2016 , 105, 2966-2973	11
164	Polymeric materials for drug release system in drug eluting stents. 2016 , 46, 317-324	11
163	Gemcitabine-based polymer-drug conjugate for enhanced anticancer effect in colon cancer. 2016 , 513, 564-571	13
162	USP7 promotes cell proliferation through the stabilization of Ki-67 protein in non-small cell lung cancer cells. 2016 , 79, 209-221	40
161	The mitochondrion interfering compound NPC-26 exerts potent anti-pancreatic cancer cell activity in vitro and in vivo. 2016 , 37, 15053-15063	10
160	Apoptosis Markers in Breast Cancer Therapy. 2016 , 74, 143-93	23
159	Profiling ribonucleotide and deoxyribonucleotide pools perturbed by gemcitabine in human non-small cell lung cancer cells. 2016 , 6, 37250	9
158	Exploring the Potent Inhibition of CTP Synthase by Gemcitabine-5'-Triphosphate. 2016 , 17, 2240-2249	9
157	Docetaxel-loaded liposomes: The effect of lipid composition and purification on drug encapsulation and in vitro toxicity. 2016 , 514, 150-159	49
156	Neoadjuvant chemotherapy of triplet regimens of docetaxel/cisplatin/5-FU (DCF NAC) may improve patient prognosis of cStage II/III esophageal squamous cell carcinoma-propensity score analysis. 2016 , 64, 209-15	12
155	Novel folate-targeted docetaxel-loaded nanoparticles for tumour targeting: in vitro and in vivo evaluation. 2016 , 6, 64306-64314	4
154	Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer. 2016 , 35, 70	12
153	Selective interaction of PEGylated polyglutamic acid nanocapsules with cancer cells in a 3D model of a metastatic lymph node. 2016 , 14, 51	11
152	Electrochemical DNA biosensor based on poly(2,6-pyridinedicarboxylic acid) modified glassy carbon electrode for the determination of anticancer drug gemcitabine. 2016 , 154, 312-21	29
151	Genomic signatures for paclitaxel and gemcitabine resistance in breast cancer derived by machine learning. <i>Molecular Oncology</i> , 2016 , 10, 85-100	7.9 73
150	Establishment and characterization of a canine soft tissue sarcoma patient-derived xenograft model. 2017 , 15, 754-763	2

149	Pharmacotherapy for treating metastatic clear cell renal cell carcinoma. 2017 , 18, 205-216	5
148	Antitumoral effect and reduced systemic toxicity in mice after intra-tumoral injection of an in vivo solidifying calcium sulfate formulation with docetaxel. 2017 , 114, 186-193	9
147	Dendrimers as nanocarriers for nucleoside analogues. 2017 , 114, 43-56	20
146	Ku70 inhibits gemcitabine-induced DNA damage and pancreatic cancer cell apoptosis. 2017 , 484, 746-752	9
145	Trachycladines and Analogues: Synthesis and Evaluation of Anticancer Activity. 2017 , 12, 448-455	3
144	Mechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancer. 2017 , 57, 16-27	107
143	Gemcitabine induced cardiomyopathy: a case of multiple hit cardiotoxicity. 2017 , 4, 71-74	8
142	Overcoming platinum resistance in ovarian cancer treatment: from clinical practice to emerging chemical therapies. 2017 , 18, 1443-1455	20
141	Conversion surgery after combination chemotherapy of docetaxel, cisplatin and S-1 (DCS) for far-advanced gastric cancer. 2017 , 47, 1249-1258	21
140	Microtubule Targeting Agents in Cancer Therapy: Elucidating the Underlying Molecular Mechanisms. 2017 , 15-65	4
139	Current FDA-approved treatments for non-small cell lung cancer and potential biomarkers for its detection. 2017 , 90, 24-37	27
138	Comparison of predictability for human pharmacokinetics parameters among monkeys, rats, and chimeric mice with humanised liver. 2017 , 47, 1052-1063	32
137	Gemcitabine: Selective cytotoxicity, induction of inflammation and effects on urothelial function. 2017 , 316, 1-9	6
136	Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. 2017 , 357, 1156-1160	577
135	Phase I study of veliparib in combination with gemcitabine. 2017 , 80, 631-643	9
134	Cholesterol derivative-based liposomes for gemcitabine delivery: preparation, in vitro, and in vivo characterization. 2017 , 43, 2016-2025	9
133	Control of Nucleotide Metabolism Enables Mutant p53's Oncogenic Gain-of-Function Activity. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3 4
132	Fabrication and Cytotoxicity of Gemcitabine-Functionalized Magnetite Nanoparticles. 2017 , 22,	25

131	The Role of Platelet-Derived ADP and ATP in Promoting Pancreatic Cancer Cell Survival and Gemcitabine Resistance. 2017 , 9,	24
130	The potential of radiolabeled chemotherapeutics in tumor diagnosis: Preliminary investigations with Ga-gemcitabine. 2018 , 79, 111-118	
129	Gemcitabine alters the proteasome composition and immunopeptidome of tumour cells. 2018 , 7, e1438107	25
128	Molecular and cellular mechanisms of chemoresistance in pancreatic cancer. 2018 , 68, 77-87	84
127	Mixed Liposome Approach for Ratiometric and Sequential Delivery of Paclitaxel and Gemcitabine. 2018 , 19, 693-699	12
126	The Emerging Role of Cyclin-Dependent Kinases (CDKs) in Pancreatic Ductal Adenocarcinoma. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3 35
125	A phase 1/2 dose-finding, safety, and activity study of cabazitaxel in pediatric patients with refractory solid tumors including tumors of the central nervous system. 2018 , 65, e27217	4
124	Aerosol Gemcitabine after Amputation Inhibits Osteosarcoma Lung Metastases but Not Wound Healing. 2018 , 2018, 3143096	1
123	Renal Toxicology/Nephrotoxicity of Cisplatin and Other Chemotherapeutic Agents. 2018 , 452-486	1
122	Targeting DNA Methyltransferases in Urological Tumors. 2018 , 9, 366	24
121	Modeling chemotherapy-induced stress to identify rational combination therapies in the DNA damage response pathway. 2018 , 11,	34
120	On the design principles of peptide-drug conjugates for targeted drug delivery to the malignant tumor site. 2018 , 14, 930-954	73
119	Saracatinib Inhibits Middle East Respiratory Syndrome-Coronavirus Replication In Vitro. 2018 , 10,	58
118	PEGylation of Carbonate Apatite Nanoparticles Prevents Opsonin Binding and Enhances Tumor Accumulation of Gemcitabine. 2018 , 107, 2497-2508	16
117	Gemcitabine-loaded DSPE-PEG-PheoA liposome as a photomediated immune modulator for cholangiocarcinoma treatment. 2018 , 183, 139-150	32
116	Should We Keep Walking along the Trail for Pancreatic Cancer Treatment? Revisiting TNF-Related Apoptosis-Inducing Ligand for Anticancer Therapy. 2018 , 10,	21
115	Mesenchymal stem cells preserve their stem cell traits after exposure to antimetabolite chemotherapy. 2019 , 40, 101536	11
114	Optimizing pharmacokinetics of intravesical chemotherapy for bladder cancer. 2019 , 16, 599-612	13

113	Gemcitabine Combination Nano Therapies for Pancreatic Cancer. 2019 , 11,		32
112	The DNA repair helicase RECQ1 has a checkpoint-dependent role in mediating DNA damage responses induced by gemcitabine. 2019 , 294, 15330-15345		9
111	Durable Control of Mycosis Fungoides after Sepsis: "Coley's Toxin?" Case Report and Review of the Literature. 2019 , 2019, 1507014		
110	Interstitial Flow Recapitulates Gemcitabine Chemoresistance in A 3D Microfluidic Pancreatic Ductal Adenocarcinoma Model by Induction of Multidrug Resistance Proteins. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	20
109	Chemoresistance in Pancreatic Cancer. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	129
108	Formulating a single thioether-bridged oleate prodrug into a self-nanoemulsifying drug delivery system to facilitate oral absorption of docetaxel. 2019 , 7, 1117-1131		15
107	Mechanisms of gemcitabine oral absorption as determined by in situ intestinal perfusions in mice. 2019 , 168, 57-64		4
106	Marine anticancer drugs and their relevant targets: a treasure from the ocean. 2019 , 27, 491-515		14
105	Alternative splicing in lung cancer. 2019 , 1862, 194388		26
104	Co-encapsulation of docetaxel and cyclosporin A into SNEDDS to promote oral cancer chemotherapy. 2019 , 26, 542-550		11
103	A novel gemcitabine derivative-loaded liposome with great pancreas-targeting ability. 2019 , 40, 1448-1456		10
102	A phase I study of gemcitabine + dasatinib (gd) or gemcitabine + dasatinib + cetuximab (GDC) in refractory solid tumors. 2019 , 83, 1025-1035		3
101	Signaling dynamics of DNA damage response invoked by combination therapy are dose-dependent. 2019 , 294, 2191		2
100	Mesothelin and TGF- β predict pancreatic cancer cell sensitivity to EGFR inhibitors and effective combination treatment with trametinib. <i>PLoS ONE</i> , 2019 , 14, e0213294	3.7	4
99	Phototriggered Release of a Transmembrane Chloride Carrier from an o-Nitrobenzyl-Linked Procarrier. 2019 , 131, 5408-5412		11
98	Phototriggered Release of a Transmembrane Chloride Carrier from an o-Nitrobenzyl-Linked Procarrier. 2019 , 58, 5354-5358		27
97	Two synchronous malignancies: nodular melanoma and renal cell carcinoma in a patient with an underlying germline mutation. 2019 , 12,		1
96	Influence of 2'-fluoro modification on glycosidic bond stabilities and gas-phase ion structures of protonated pyrimidine nucleosides. 2019 , 219, 10-22		10

95	Forty years of cisplatin-based chemotherapy in muscle-invasive bladder cancer: are we understanding how, who and when?. 2019 , 37, 1759-1765	7
94	1-Palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol (PLAG) attenuates gemcitabine-induced neutrophil extravasation. 2019 , 9, 4	11
93	EU-OPENSREEN: A Novel Collaborative Approach to Facilitate Chemical Biology. 2019 , 24, 398-413	7
92	Gemcitabine nanoparticles promote antitumor immunity against melanoma. 2019 , 189, 48-59	53
91	Novel insights into molecular chaperone regulation of ribonucleotide reductase. 2019 , 65, 477-482	15
90	DHS (trans-4,4'-dihydroxystilbene) suppresses DNA replication and tumor growth by inhibiting RRM2 (ribonucleotide reductase regulatory subunit M2). 2019 , 38, 2364-2379	28
89	Overview of systemic treatment in recurrent and advanced cervical cancer: a primer for radiologists. 2019 , 44, 1506-1519	8
88	A phase II study of neoadjuvant chemotherapy with docetaxel, cisplatin, and S-1, followed by gastrectomy with D2 lymph node dissection for high-risk advanced gastric cancer: results of the KDOG1001 trial. 2019 , 22, 598-606	17
87	Nucleoside analogs as a radiosensitizer modulating DNA repair, cell cycle checkpoints, and apoptosis. 2020 , 39, 439-452	2
86	Overview of imaging findings associated with systemic therapies in advanced epithelial ovarian cancer. 2020 , 45, 828-841	2
85	Comparative pharmacokinetic study of PEGylated gemcitabine and gemcitabine in rats by LC-MS/MS coupled with pre-column derivatization and MS technique. 2020 , 206, 120184	10
84	Computational modeling of therapy on pancreatic cancer in its early stages. 2020 , 19, 427-444	7
83	Chemotherapy in chronic kidney disease and dialysis. 2020 , 183-196.e7	
82	Combination Intravesical Therapy. 2020 , 47, 83-91	1
81	Electrochemotherapy with Irreversible Electroporation and FOLFIRINOX Improves Survival in Murine Models of Pancreatic Adenocarcinoma. 2020 , 27, 4348-4359	9
80	Mechanistic Multiscale Pharmacokinetic Model for the Anticancer Drug 2',2'-difluorodeoxycytidine (Gemcitabine) in Pancreatic Cancer. 2020 , 13, 608-617	1
79	Human intratumoral therapy: Linking drug properties and tumor transport of drugs in clinical trials. 2020 , 326, 203-221	10
78	Erythrocyte Characteristics and the Risk of Depression in Late Life: A Population-Based Prospective Study. 2020 , 21, 1677-1683	0

77	TGF- β Downregulation overcomes gemcitabine resistance in oral squamous cell carcinoma. 2020 , 29, 179-187	3
76	Recent discovery and development of inhibitors targeting coronaviruses. 2020 , 25, 668-688	211
75	Highly proliferative anal neuroendocrine carcinoma: molecular and clinical features of a rare, recurrent case in complete remission. 2020 , 20, 290	1
74	Pharmacokinetics of gemcitabine and its amino acid ester prodrug following intravenous and oral administrations in mice. 2020 , 180, 114127	6
73	Why Great Mitotic Inhibitors Make Poor Cancer Drugs. 2020 , 6, 924-941	17
72	Targeting Pancreatic Cancer Cells and Stellate Cells Using Designer Nanotherapeutics in vitro. 2020 , 15, 991-1003	10
71	Circular RNAs: Potential Regulators of Treatment Resistance in Human Cancers. 2019 , 10, 1369	20
70	Pilot Study to Predict Pharmacokinetics of a Therapeutic Gemcitabine Dose From a Microdose. 2020 , 9, 929-937	1
69	Advances in engineering local drug delivery systems for cancer immunotherapy. 2020 , 12, e1632	17
68	Senescence-Induced Vascular Remodeling Creates Therapeutic Vulnerabilities in Pancreas Cancer. 2020 , 181, 424-441.e21	96
67	Elimination of senescent cells by β -galactosidase-targeted prodrug attenuates inflammation and restores physical function in aged mice. 2020 , 30, 574-589	75
66	Therapeutic resistance of pancreatic cancer: Roadmap to its reversal. 2021 , 1875, 188461	19
65	Modulation of Cancer-Associated Fibrotic Stroma by An Integrin β Targeting Protein for Pancreatic Cancer Treatment. 2021 , 11, 161-179	7
64	Design, synthesis, and evaluation of liver-specific gemcitabine prodrugs for potential treatment of hepatitis C virus infection and hepatocellular carcinoma. 2021 , 213, 113135	1
63	A <i>Drosophila</i> platform identifies a novel, personalized therapy for a patient with adenoid cystic carcinoma. <i>IScience</i> , 2021 , 24, 102212	6.1 4
62	Synergistic Pharmacodynamic Effects of Gemcitabine and Fibroblast Growth Factor Receptor Inhibitors on Pancreatic Cancer Cell Cycle Kinetics and Proliferation. 2021 , 377, 370-384	1
61	The emerging relationship between metabolism and DNA repair. 2021 , 20, 943-959	3
60	Modeling breast cancer by grafting patient tumor samples in the avian embryo: an in vivo platform for therapy evaluation coupled to large scale molecular analyses.	

59	Novel Pharmacological Options in the Treatment of Cholangiocarcinoma: Mechanisms of Resistance. 2021 , 13,		3
58	Clinical Principles and Applications of Chemoirradiation. 2006 , 39-55		3
57	Cancer Survivorship Issues in Older Adults. 2007 , 215-224		2
56	Lympho-Hematopoietic Stem Cells and Their Aging. 2009 , 573-588		1
55	Cytogenetic Abnormalities Associated with Endocrine Neoplasia. 1997 , 369-401		1
54	Von Hippel-Lindau syndrome: hereditary cancer arising from inherited mutations of the VHL tumor suppressor gene. 1996 , 88, 13-39		11
53	Pharmaceutical Technology for Improving the Bioavailability of Natural Products. 2020 , 1-32		1
52	Aerosolized Chemotherapy for Osteosarcoma. <i>Advances in Experimental Medicine and Biology</i> , 2020 , 1257, 67-73	3.6	2
51	Infectious Diseases in Cancer Patients: An Overview. 2015 , 295-311		2
50	Chemotherapy in Head and Neck Squamous Cell Cancer. 2016 , 53-68		1
49	Renal Cell Adenoma and Carcinoma, Rat. <i>Monographs on Pathology of Laboratory Animals</i> , 1998 , 79-118		2
48	Bronchialkarzinom. 2004 , 1325-1355		1
47	Urinary tract. 2011 , 1101-1286		8
46	Cellular Mechanisms of Age-Related Bone Loss. 1999 , 145-157		10
45	Cyclin-dependent kinases as targets for cancer therapy. <i>Cancer Chemotherapy and Biological Response Modifiers</i> , 2003 , 21, 145-70		15
44	Cyclin-dependent kinases as targets for cancer therapy. <i>Cancer Chemotherapy and Biological Response Modifiers</i> , 2005 , 22, 135-62		13
43	Conjugates, PolymerâDrug: Targeted Cancer Treatment. 2089-2112		2
42	Algorithmic modeling quantifies the complementary contribution of metabolic inhibitions to gemcitabine efficacy. <i>PLoS ONE</i> , 2012 , 7, e50176	3.7	16

41	Meta-analysis of gemcitabine in brief versus prolonged low-dose infusion for advanced non-small cell lung cancer. <i>PLoS ONE</i> , 2018 , 13, e0193814	3.7	4
40	Gemcitabine: Future Prospects of Single-Agent and Combination Studies. <i>Oncologist</i> , 1997 , 2, 127-134	5.7	66
39	Taxotere: Clinical Trials in Non-Small Cell Lung Cancer. <i>Oncologist</i> , 1998 , 3, 86-93	5.7	6
38	Understanding the Mechanism of Cell Death in Gemcitabine Resistant Pancreatic Ductal Adenocarcinoma: A Systems Biology Approach. <i>Current Genomics</i> , 2019 , 20, 483-490	2.6	1
37	Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation. <i>Health Technology Assessment</i> , 2015 , 19, 1-480	4.4	20
36	Extracellular Matrix Composition Modulates the Responsiveness of Differentiated and Stem Pancreatic Cancer Cells to Lipophilic Derivate of Gemcitabine. <i>International Journal of Molecular Sciences</i> , 2020 , 22,	6.3	3
35	Use of -paclitaxel and gemcitabine in pancreatic cancer without granulocyte colony-stimulating factor: A multicenter real-world experience. <i>Journal of Oncology Pharmacy Practice</i> , 2021 , 10781552211038677	1.7	17
34	Familiäre Tumorerkrankungen. 2000 , 275-302		
33	Geriatrische Onkologie. 2000 , 589-597		
32	Diagnostische Besonderheiten. 2002 , 195-207		
31	Taxotere 114977-28-5.		
30	Ovarian cancer in older women. <i>Aging Health</i> , 2006 , 2, 437-447		
29	Nonsurgical Management of Metastatic Renal Cell Carcinoma. 2008 , 281-297		
28	Epidemiology of Renal Tumors. 2008 , 73-96		
27	Beyond BCG: Gemcitabine. 2009 , 115-125		
26	PEGânticancer Drugs. 2010 , 221-263		
25	Particularit�s de lâusage des agents cytotoxiques chez le sujet g�. 2010 , 75-83		
24	Radiotherapy and Chemotherapy. 2010 , 82-94		

23	Docetaxel. 2010 , 133-146		1
22	Treatment of Acute Lymphoblastic Leukemia in Middle-Age and Older Adults. 2011 , 115-126		
21	Nucleoside Analogs in the Therapy of T-Cell Malignancies. 2013 , 263-278		
20	Molecular Pathology and Diagnostics of Non-small Cell Lung Carcinoma. 2014 , 75-118		
19	Pyrimidine Antimetabolites?. 2014 ,		
18	The Taxoids. 1997 , 175-193		
17	New Drugs in Lung Cancer. <i>Medical Radiology</i> , 1999 , 249-266		0.2
16	Single-agent paclitaxel in patients with metastatic breast cancer receiving high-dose chemotherapy with peripheral blood stem cell support. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1999 , 22, 162-7		2.7
15	Renal Cell Carcinoma: From Molecular Biology to Targeted Therapies. 2015 , 555-575		
14	Tumors of the urinary tract. 401-425		
13	Breast Cancer. 2017 ,		
12	Kidney Cancer: From Basics to Immunotherapy. 2019 , 625-657		
11	Cancer in the Older Population. 2006 , 1717-1729		
10	Troxacitabine (Troxatyl ®) 2006 , 199-214		
9	An avian embryo patient-derived xenograft model for preclinical studies of human breast cancers. <i>IScience</i> , 2021 , 24, 103423	6.1	0
8	Potential Role of Exosomes in the Chemoresistance to Gemcitabine and Nab-Paclitaxel in Pancreatic Cancer.. <i>Diagnostics</i> , 2022 , 12,	3.8	3
7	Nucleotide biosynthesis links glutathione metabolism to ferroptosis sensitivity.. <i>Life Science Alliance</i> , 2022 , 5,	5.8	1
6	microRNA-99a-5p induces cellular senescence in gemcitabine-resistant bladder cancer by targeting SMARCD1.. <i>Molecular Oncology</i> , 2022 ,	7.9	0

5	Integrin-Mediated Targeted Cancer Therapy Using c(RGDyK)-Based Conjugates of Gemcitabine.. <i>Journal of Medicinal Chemistry</i> , 2021 ,	8.3	1
4	Microangiopathy associated with gemcitabine: a drug interaction with nab-paclitaxel? A case series and literature review.. <i>European Journal of Clinical Pharmacology</i> , 2022 , 1	2.8	0
3	PD-L1 Mediates IFN γ Regulation of Glucose but Not of Tryptophan Metabolism in Clear Cell Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2022 , 12,	5.3	1
2	Retrospective Analysis of the Efficacy and Tolerability of Gemcitabine-based Chemotherapy in Relapsed/Refractory Lymphoma Patients Not Eligible for Stem Cell Transplant. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022 ,	2	0
1	Design, synthesis and antitumor activity study of a gemcitabine prodrug conjugated with a HDAC6 inhibitor. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2022 , 72, 128881	2.9	0